Klin Farmakol Farm. 2003;17(2):113-114

Prevence cévní mozkové příhody a systémové embolie u pacientů s fibrilací síní

Miroslav Souček, Petr Fráňa, Ivan Řiháček
II. interní klinika FN u sv. Anny LF MU, Brno

Keywords: Ximelagatran, atrial fibrillation, vascular brain attack, Warfarin.

Published: December 31, 2003  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Souček M, Fráňa P, Řiháček I. Prevence cévní mozkové příhody a systémové embolie u pacientů s fibrilací síní. Klin Farmakol Farm. 2003;17(2):113-114.

Článek je věnován skončené studii Sportif III, která porovnávala účinek nového perorálního léku Ximelagatranu s osvědčenou léčbou Warfarinem u pacientů s fibrilací síní. Hlavním cílem bylo porovnat výskyt cévních mozkových příhod a dalších embolií do periferie.

Prevention of vascular brain attack and systemic embolism in patients with atrial fibrillation

Article deals with finished Sportif III study, which has compared an action of new oral medication Ximelagatran with standing treatment of atrial fibrillation by Warfarin. Comparison of vascular brain attack and other peripheral embolism incidence was a main goal.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: the Framingham Study. Arch Intern Med 1987; 147: 1561-1564. Go to original source...
    2. Wolf PA, Abbott RD, Kannel Wb. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-988. Go to original source... Go to PubMed...
    3. Alberts GW, Dalen JE, Laupacis A, et al. Antitrombotic therapy in atrial fibrillation. Chest 2001; 119 (Suppl: 194S-206S). Go to original source... Go to PubMed...
    4. Hart RG, Benavente O, McBride R, et al. Antitrombotic therapy to prevent stroke in patiens with atrial fibrillation: a metaanalysis. Ann Intern Med 1999; 131: 492-501. Go to original source... Go to PubMed...
    5. European Atrial Fibrillation Trial (EAFT) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic atack or minor stroke. Lancet 1993; 342: 1255-1262. Go to original source...
    6. Bungard TJ, Ghali WA, Teo KK, et al. Why patiens with atrial fibrillation don´t receive warfarin? Arch Intern Med 2000; 160: 41-46. Go to original source... Go to PubMed...
    7. Grind M, Hamren B, Bääthe S, et al. Pharmakokinetics of the oral direct trombin ximelagatran in patiens with nonvalvular atrial fibrillation receiving long-term treatment: a population analysis by nonlinear mixed effect modeling. Clin Pharmacol Ther 2002; 71: 31.
    8. Ericsson BI, Bergqvist D, Kälebo P, et al. A randomised, controlled study of the oral direct trombin inhibitor, ximelagatran (pINN, formely H 376/95), and its active form, melagatran, compared with dalteparin as thromboprophylaxis after total hip or total knee replacement: METHRO II. Lancet 2002; 360: 1441-1447. Go to original source... Go to PubMed...
    9. Heit JA, Colwell CW, Francis CW, et al., for the AstraZeneca Arthroplasty Study Group. Comparison of the oral direct trombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous tromboembolism after total knee replacement: a phase 2 dose-finding study. Arch Intern Med 2001; 161: 2215-2221. Go to original source... Go to PubMed...
    10. Carlson MK, Gleason PP, Sen S. Elevation of hepatic transaminases after enoxaparin use: case report and review of unfractionated and low-molecular-weight heparin-induced hepatotoxicity. Pharmacotherapy 2001; 21: 108-113. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.